“The Evolution of Lymphangioleiomyomatosis (LAM) Management: From Hormonal Manipulation to Targeted Inhibition of the mammalian target of rapamycin (mTOR) Pathway”, RSD, vol. 14, no. 4, p. e4614448656, Apr. 2025, doi: 10.33448/rsd-v14i4.48656.